Lower HDL-C and apolipoprotein A-I are related to higher glomerular filtration rate in subjects without kidney disease

Journal of Lipid Research

Volumn 51, Issue 7, 2010, Pages 1982-1990

  Krikken, Jan A ^a   Gansevoort, Ron T ^a   Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apolipoprotein A II; Creatinine clearance; e GFR; HDL cholesterol

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; CREATININE;

ADULT; AGED; ALBUMINURIA; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN RESISTANCE; MALE; OBESITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; ANIMAL; KIDNEY; KIDNEY DISEASE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; QUESTIONNAIRE; URINE;

ADULT; AGED; ALBUMINURIA; ANIMALS; APOLIPOPROTEIN A-I; CHOLESTEROL, HDL; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INSULIN RESISTANCE; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; QUESTIONNAIRES; TRIGLYCERIDES;

EID: 77953490674     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M005348     Document Type: Article

References (52)

1. Vega, G. L., and S. M. Grundy. 1996. Hypoalphalipoproteinemia (low high density lipoprotein cholesterol) as a risk factor for coronary heart disease. Curr. Opin. Lipidol. 7: 209-216. (Pubitemid 26280230)
2. Lewington, S., G. Whitlock, R. Clarke, P. Sherliker, J. Emberson, J. Halsey, N. Qizilbash, P. Peto, and R. Collins. 2007. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 207: 1829-1839.
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. 2002. Circulation. 106: 3143-3421.
4. Borggreve, S. E., R. de Vries, and R. P. F. Dullaart. 2003. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur. J. Clin. Invest. 33: 1051-1069.
5. Linsel-Nitschke, P., and A. R. Tall. 2005. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat. Rev. Drug Discov. 4: 193-205.
6. Singh, I. M., M. H. Shishehbor, and B. J. Ansell. 2007. High-density lipoprotein as a therapeutic target: a systematic review. J. Am. Med. Assoc. 298: 786-798.
7. Dullaart, R. P. F., G. M. Dallinga-Thie, B. H. R. Wolffenbuttel, and A. van Tol. 2007. CETP inhibition in cardiovascular risk management: a critical appraisal. Eur. J. Clin. Invest. 37: 90-98.
8. Lewis, G. F., and D. J. Rader. 2005. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96: 1221-1232.
9. Moestrup, S. K., and R. Kozyraki. 2000. Cubilin, a high-density lipoprotein receptor. Curr. Opin. Lipidol. 11: 133-140.
10. Moestrup, S. K., and L. B. Nielsen. 2005. The role of the kidney in lipid metabolism. Curr. Opin. Lipidol. 16: 301-306.
11. Glass, C. K., R. C. Pittman, G. A. Keller, and D. Steinberg. 1983. Tissue sites of degradation of apoprotein A-I in the rat. J. Biol. Chem. 258: 7161-7167.
12. Braschi, S., T. A. Neville, C. Maugeais, T. A. Ramsamy, R. Seymour, and D. L. Sparks. 2000. Role of the kidney in regulating the metabolism of HDL in rabbits: evidence that iodination alters the catabolism of apolipoprotein A-I by the kidney. Biochemistry. 39: 5441-5449.
13. Woollett, L. A., and D. K. Spady. 1997. Kinetic parameters for high density lipoprotein apoprotein AI and cholesteryl ester transport in the hamster. J. Clin. Invest. 99: 1704-1713.
14. Dallinga-Thie, G. M., F. M. van 't Hooft, and A. van Tol. 1986. Tissue sites of high density lipoprotein A-IV in rats. Arteriosclerosis. 6: 277-284.
15. Kozyraki, R., J. Fyfe, M. Kristiansen, C. Gerdes, C. Jacobsen, S. Cui, E. I. Christensen, M. Aminoff, A. de la Chapelle, R. Krahe, et al. 1999. The intrinsic factor-vitamin B12 receptor, cubilin, is a highaffi nity apolipoprotein A-I receptor facilitating endocytosis of highdensity lipoprotein. Nat. Med. 5: 656-661.
16. Hammad, S. M., J. L. Barth, C. Knaak, and W. S. Argraves. 2000. Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins. J. Biol. Chem. 275: 12003-12008.
17. Horowitz, B. S., I. J. Goldberg, J. Merab, T. M. Vanni, R. Ramakrishnan, and H. N. Ginsberg. 1993. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J. Clin. Invest. 91: 1743-1752.
18. Vaziri, N. D. 2006. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am. J. Physiol. Renal Physiol. 290: F262-F272.
19. Muntner, P., L. L. Hamm, J. W. Kusek, J. Chen, P. K. Whelton, and J. He. 2004. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann. Intern. Med. 140: 9-17.
20. Chen, J., P. Muntner, L. L. Hamm, D. W. Jones, V. Batuman, V. Fonseca, P. K. Whelton, and J. He. 2004. The metabolic syndrome and chronic kidney disease in US adults. Ann. Intern. Med. 140: 167-174.
21. Shlipak, M. G., L. F. Fried, M. Cushman, T. A. Manolio, D. Peterson, C. Stehman-Breen, A. Bleyer, A. Newman, D. Siscovick, and B. Psaty. 2005. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 13: 1737-1745.
22. Parikh, N. I., S. J. Hwang, M. G. Larson, J. B. Meigs, D. Levy, and C. S. Fox. 2006. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch. Intern. Med. 166: 1884-1891.
23. Lo, J. C., A. S. Go, M. Chandra, D. Fan, and G. A. Kaysen. 2007. GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD. Am. J. Kidney Dis. 50: 552-558.
24. Verhave, J. C., H. L. Hillege, J. G. Burgerhof, R. T. Gansevoort, D. de Zeeuw, and P. E. de Jong; PREVEND Study Group. 2005. The association between atherosclerotic risk factors and renal function in the general population. Kidney Int. 67: 1967-1973.
25. de Boer, I. H., B. C. Astor, H. Kramer, W. Palmas, S. L. Seliger, M. G. Shlipak, D. S. Siscovick, M. Y. Tsai, and B. Kestenbaum. 2008. Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis. Clin. J. Am. Soc. Nephrol. 3: 125-132.
26. Dengel, D. R., A. P. Goldberg, R. S. Mayuga, G. M. Kairis, and M. R. Weir. 1996. Insulin resistance, elevated glomerular filtration fraction, and renal injury. Hypertension. 28: 127-132.
27. Krikken, J. A., A. T. Lely, S. J. Bakker, and G. Navis. 2007. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int. 71: 260-265.
28. Borggreve, S. E., H. L. Hillege, B. H. Wolffenbuttel, P. E. de Jong, S. J. Bakker, G. van der Steege, A. van Tol, and R. P. Dullaart; PREVEND Study Group. 2005. The effect of cholesteryl ester transfer protein -629C->A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides. J. Clin. Endocrinol. Metab. 90: 4198-4204.
29. Hillege, H. L., W. M. Janssen, A. A. Bak, G. F. Diercks, D. E. Grobbee, H. J. Crijns, W. H. Van Gilst, D. De Zeeuw, and P. E. De Jong; Prevend Study Group. 2001. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J. Intern. Med. 249: 519-526.
30. Pinto-Sietsma, S. J., W. M. T. Janssen, H. L. Hillege, G. Navis, and P. E. de Jong. 2000. Urinary albumin excretion is associated with renal functional abnormalities in a non-diabetic population. J. Am. Soc. Nephrol. 11: 1882-1888.
31. Gansevoort, R. T., J. C. Verhave, H. L. Hillege, J. G. Burgerhof, S. J. Bakker, D. de Zeeuw, and P. E. de Jong; for the PREVEND Study Group. 2005. The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int. Suppl. 94: S28-S35.
32. Lambers Heerspink, H. J., A. H. Brantsma, D. de Zeeuw, S. J. Bakker, P. E. de Jong, and R. T. Gansevoort; PREVEND Study Group. 2008. Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am. J. Epidemiol. 168: 897-905.
33. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 1997. Report of the Expert Committee on the Diagnosis and Classification of diabetes mellitus. Diabetes Care. 20: 1183-1197.
34. Matthews, D. R., J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28: 412-419.
35. Levey, A. S., J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth. 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 130: 461-470.
36. Levey, A. S., L. A. Stevens, C. H. Schmid, Y. L. Zhang, A. F. Castro 3rd, H. I. Feldman, J. W. Kusek, P. Eggers, F. Van Lente, T. Greene, et al. 2009. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150: 604-612.
37. Dubois, D., and E. F. DuBois. 1916. A formula to estimate the approximate surface area if height and weight be known. Arch. Intern. Med. 17: 863-871.
38. Warnick, G. R., M. Nauck, and N. Rifai. 2001. Evolution of methods for measurement of HDL cholesterol: from ultracentrifugation to homogenous assays. Clin. Chem. 47: 1579-1596.
39. Steinmetz, J., P. Tarallo, B. Fournier, E. Caces, and G. Siest. 1995. Reference limits of apolipoprotein A-I and apolipoprotein B using an IFCC standardized immunonephelometric method. Eur. J. Clin. Chem. Clin. Biochem. 33: 337-342.
40. Retnakaran, R., P. W. Connelly, S. B. Harris, B. Zinman, and A. J. Hanley. 2007. Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth. Pediatr. Nephrol. 22: 1007-1013.
41. Watanabe, S., T. Okura, J. Liu, K. Miyoshi, T. Fukuoka, K. Hiwada, and J. Higaki. 2003. Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens. Res. 26: 895-899.
42. Connelly, P. W., B. Zinman, G. F. Maguire, M. Mamakeesick, S. B. Harris, R. A. Hegele, R. Retnakaran, and A. J. Hanley. 2009. Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes. J. Lipid Res. 50: 1216-1222.
43. Knight, E. L., J. C. Verhave, D. Spiegelman, H. L. Hillege, D. de Zeeuw, G. C. Curhan, and P. E. de Jong. 2004. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 65: 1416-1421.
44. Stevens, L. A., C. H. Schmid, T. Greene, L. Li, G. J. Beck, M. M. Joffe, M. Froissart, J. W. Kusek, Y. L. Zhang, J. Coresh, et al. 2009. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 75: 652-660.
45. Manetti, L., E. Pardini, M. Genovesi, A. Campomori, L. Grasso, L. L. Morselli, I. Lupi, G. Pellegrini, L. Bartalena, F. Bogazzi, et al. 2005. Thyroid function differently affects serum cystatin C and creatinine concentrations. J. Endocrinol. Invest. 28: 346-349.
46. Graversen, J. H., G. Castro, A. Kandoussi, H. Nielsen, E. I. Christensen, A. Norden, and S. K. Moestrup. 2008. Pivotal role of the human kidney in catabolism of HDL protein components apolipoprotein A-I and A-IV but not of A-II. Lipids. 43: 467-470.
47. Faber, K., V. Hvidberg, S. K. Moestrup, B. Dahlbäck, and L. B. Nielsen. 2006. Megalin is a receptor for apolipoprotein M, and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M. Mol. Endocrinol. 20: 212-218.
48. Rousset, X., D. Château, D. Pastier, C. Klein, J. Demeurie, C. Cywiner-Golenzer, M. Chabert, P. Verroust, J. Chambaz, F. P. Châtelet, et al. 2007. Apolipoprotein A-II is catabolized in the kidney as a function of its plasma concentration. J. Lipid Res. 48: 2151-2161.
49. de Boer, I. H., B. C. Astor, H. Kramer, W. Palmas, K. Rudser, S. L. Seliger, M. G. Shlipak, D. S. Siscovick, M. Y. Tsai, and B. Kestenbaum. 2008. Mild elevations of urine albumin excretion are associated with atherogenic lipoprotein abnormalities in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 197: 407-414.
50. Fuh, M. M., C. M. Lee, C. Y. Jeng, D. C. Shen, S. M. Shieh, G. M. Reaven, and Y. D. Chen. 1990. Effect of chronic renal failure on high-density lipoprotein kinetics. Kidney Int. 37: 1295-1300. (Pubitemid 20148554)
51. Okubo, K., K. Ikewaki, S. Sakai, N. Tada, Y. Kawaguchi, and S. Mochizuki. 2004. Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: a stable isotope study. J. Am. Soc. Nephrol. 15: 1008-1015.
52. Tomaszewski, M., F. J. Charchar, C. Maric, J. McClure, L. Crawford, W. Grzeszczak, N. Sattar, E. Zukowska-Szczechowska, and A. F. Dominiczak. 2007. Glomerular hyperfiltration: a new marker of metabolic risk. Kidney Int. 71: 816-821.